Institution
University of Córdoba (Spain)
Education•Cordova, Spain•
About: University of Córdoba (Spain) is a education organization based out in Cordova, Spain. It is known for research contribution in the topics: Population & Catalysis. The organization has 12006 authors who have published 22998 publications receiving 537842 citations. The organization is also known as: University of Córdoba (Spain) & Universidad de Córdoba.
Papers published on a yearly basis
Papers
More filters
••
Saarland University1, University College London2, Paris Diderot University3, Paris Descartes University4, University Hospital of Lausanne5, university of lille6, Pasteur Institute7, University of Copenhagen8, University of Genoa9, University of Helsinki10, University of Córdoba (Spain)11, Newcastle University12
TL;DR: A timely diagnosis and treatment to induce puberty can be beneficial for sexual, bone and metabolic health, and might help minimize some the psychological effects of CHH.
Abstract: Congenital hypogonadotropic hypogonadism (CHH) is a rare disorder caused by the deficient production, secretion or action of gonadotropin-releasing hormone (GnRH), which is the master hormone regulating the reproductive axis. CHH is clinically and genetically heterogeneous, with >25 different causal genes identified to date. Clinically, the disorder is characterized by an absence of puberty and infertility. The association of CHH with a defective sense of smell (anosmia or hyposmia), which is found in ∼50% of patients with CHH is termed Kallmann syndrome and results from incomplete embryonic migration of GnRH-synthesizing neurons. CHH can be challenging to diagnose, particularly when attempting to differentiate it from constitutional delay of puberty. A timely diagnosis and treatment to induce puberty can be beneficial for sexual, bone and metabolic health, and might help minimize some of the psychological effects of CHH. In most cases, fertility can be induced using specialized treatment regimens and several predictors of outcome have been identified. Patients typically require lifelong treatment, yet ∼10-20% of patients exhibit a spontaneous recovery of reproductive function. This Consensus Statement summarizes approaches for the diagnosis and treatment of CHH and discusses important unanswered questions in the field.
590 citations
••
Cedars-Sinai Medical Center1, NewYork–Presbyterian Hospital2, University of California, Los Angeles3, University of North Carolina at Chapel Hill4, University of Alabama at Birmingham5, University of California, San Francisco6, University of Hamburg7, Université catholique de Louvain8, Mayo Clinic9, Rush University Medical Center10, University of Duisburg-Essen11, University of Padua12, University of Barcelona13, Oregon Health & Science University14, Erasmus University Rotterdam15, Tufts University16, University of Córdoba (Spain)17, University of Toledo18, University of Colorado Denver19
TL;DR: This is the first prospective, randomized, controlled trial of an extracorporeal liver support system, demonstrating safety and improved survival in patients with fulminant/subfulminant hepatic failure.
Abstract: Objective: The HepatAssist liver support system is an extracorpo-real porcine hepatocyte-based bioartificial liver (BAL). The safety and efficacy of the BAL were evaluated in a prospective. random-ized, controlled, multicenter trial in patients with severe acute liver failure. Summary Background Data: In experimental animals with acute liver failure, we demonstrated beneficial effects of the BAL. Similarly, Phase I trials of the BAL in acute liver failure patients yielded promising results. Methods: A total of 171 patients (86 control and 85 BAL) were enrolled. Patients with fulminant/subfulminant hepatic failure and primary nonfunction following liver transplantation were included. Data were analyzed with and without accounting for the following confounding factors: liver transplantation, time to transplant, disease etiology, disease severity, and treatment site. Results: For the entire patient population, survival at 30 days was 71% for BAL versus 62% for control (P = 0.26). After exclusion of primary nonfunction patients, survival was 73% for BAL Versus 59% for control (it = 147; P= 0.12). When Survival was analyzed accounting for confounding factors. in the entire patient Population, there was no difference between the 2 groups (risk ratio = 0.67; P = 0.13). However, survival in fulminant/subfulminant hepatic failure patients was significantly higher in the BAL compared with the control group (risk ratio 0.56: P = 0.048). Conclusions: This is the first prospective, randomized, controlled trial of an extracorporeal liver support system, demonstrating safety and improved survival in patients with fulminant/subfulminant hepatic failure.
588 citations
••
TL;DR: The primary endpoint (pathological complete response) was previously reported and secondary endpoints reported here are 5-year progression-free survival (analysed in the intention-to-treat population) and disease- free survival ( analysed in patients who had surgery).
Abstract: Summary Background In the primary analysis of the NeoSphere trial, patients given neoadjuvant pertuzumab, trastuzumab, and docetaxel showed a significantly improved pathological complete response compared with those given trastuzumab and docetaxel after surgery. Here, we report 5-year progression-free survival, disease-free survival, and safety. Methods In this multicentre, open-label, phase 2 randomised trial in hospitals and medical clinics, treatment-naive adults with locally advanced, inflammatory, or early-stage HER2-positive breast cancer were randomly assigned (1:1:1:1) to receive four neoadjuvant cycles of trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg every 3 weeks) plus docetaxel (75 mg/m 2 every 3 weeks, increasing to 100 mg/m 2 from cycle 2 if tolerated; group A), pertuzumab (840 mg loading dose, followed by 420 mg every 3 weeks) and trastuzumab plus docetaxel (group B), pertuzumab and trastuzumab (group C), or pertuzumab and docetaxel (group D). After surgery, patients received three cycles of FEC (fluorouracil 600 mg/m 2 , epirubicin 90 mg/m 2 , and cyclophosphamide 600 mg/m 2 ) every 3 weeks (patients in group C received four cycles of docetaxel prior to FEC), and trastuzumab 6 mg/kg every 3 weeks to complete 1 year's treatment (17 cycles in total). Randomisation was done by a central centre using dynamic allocation, stratified by operable, locally advanced, and inflammatory breast cancer, and by oestrogen and/or progesterone receptor positivity. Safety analyses were done according to treatment received. The primary endpoint (pathological complete response) was previously reported; secondary endpoints reported here are 5-year progression-free survival (analysed in the intention-to-treat population) and disease-free survival (analysed in patients who had surgery). Secondary and exploratory analyses were not powered for formal statistical hypothesis testing, and therefore results are for descriptive purposes only. The study ended on Sept 22, 2014 (last patient, last visit). This study is registered with ClinicalTrials.gov, number NCT00545688. Findings Between Dec 17, 2007, and Dec 22, 2009, 417 eligible patients were randomly assigned to group A (107 patients), group B (107 patients), group C (107 patients), or group D (96 patients). One patient in group A withdrew before treatment. One patient assigned to group D received group A treatment, one patient assigned to group D received group B treatment, and one patient assigned to group B received group C treatment. At clinical cutoff, 87 patients had progressed or died. 5-year progression-free survival rates were 81% (95% CI 71–87) for group A, 86% (77–91) for group B, 73% (64–81) for group C, and 73% (63–81) for group D (hazard ratios 0·69 [95% CI 0·34–1·40] group B vs group A, 1·25 [0·68–2·30] group C vs group A, and 2·05 [1·07–3·93] group D vs group B). Disease-free survival results were consistent with progression-free survival results and were 81% (95% CI 72–88) for group A, 84% (72–91) for group B, 80% (70–86) for group C, and 75% (64–83) for group D. Patients who achieved total pathological complete response (all groups combined) had longer progression-free survival compared with patients who did not (85% [76–91] in patients who achieved total pathological response vs 76% [71–81] in patients who did not achieve total pathological response; hazard ratio 0·54 [95% CI 0·29–1·00]). There were no new or long-term safety concerns and tolerability was similar across groups (neoadjuvant and adjuvant treatment periods combined). The most common grade 3 or worse adverse events were neutropenia (group A: 71 [66%] of 107 patients; group B: 59 [55%] of 107; group C: 40 [37%] of 108; group D: 60 [64%] of 94), febrile neutropenia (group A: 10 [9%]; group B: 12 [11%]; group C: 5 [5%]; group D: 15 [16%]), and leucopenia (group A: 13 [12%]; group B: 6 [6%]; group C: 4 [4%]; group D: 8 [9%]). The number of patients with one or more serious adverse event was similar across groups (19–22 serious adverse events per group in 18–22% of patients). Interpretation Progression-free survival and disease-free survival at 5-year follow-up show large and overlapping CIs, but support the primary endpoint (pathological complete response) and suggest that neoadjuvant pertuzumab is beneficial when combined with trastuzumab and docetaxel. Additionally, they suggest that total pathological complete response could be an early indicator of long-term outcome in early-stage HER2-positive breast cancer. Funding F Hoffmann-La Roche.
572 citations
••
TL;DR: It is demonstrated that the non-parametric NOISeqBIO efficiently controls false discoveries in experiments with biological replication and outperforms state-of-the-art methods.
Abstract: European Union Seventh Framework Programme [FP7/2007-2013, 306000]; Spanish Ministry of Science and Innovation [MICINN, BIO2008-04638-E], in the framework of ERA-Net Pathogenomics; MICINN [DPI2008-06880-C03-03/DPI]. Funding for open access charge: University of Florida, Publication Funds.
547 citations
••
TL;DR: In this paper, the authors provide a brief overview of the complex biofuel issue, providing the latest update of the production and potential of biofuels in the transport sector including types of biofuel, feedstocks and technologies and some of the possible socioeconomic, environmental and political implications of the widespread use of bio fuels in our society.
Abstract: Environmental issues, the growing demand for energy, political concerns and the medium-term depletion of petroleum has created the need for development of sustainable technologies based on renewable raw materials. Biofuels might help to meet the future energy supply demands as well as contributing to a reduction of green house gas emissions. Although this topic is highly controversial and many investigations are currently ongoing, this review is intended to give a brief overview about certain aspects of the complex biofuel issue, providing the latest update of the production and potential of biofuels in the transport sector including types of biofuel, feedstocks and technologies and some of the possible socio-economic, environmental and political implications of the widespread use of biofuels in our society.
542 citations
Authors
Showing all 12089 results
Name | H-index | Papers | Citations |
---|---|---|---|
Jose M. Ordovas | 123 | 1024 | 70978 |
Liang Cheng | 116 | 1779 | 65520 |
Pedro W. Crous | 115 | 809 | 51925 |
Munther A. Khamashta | 109 | 623 | 50205 |
Luis Serrano | 105 | 452 | 42515 |
Raymond Vanholder | 103 | 841 | 40861 |
Carlos Dieguez | 101 | 545 | 36404 |
David G. Bostwick | 99 | 403 | 31638 |
Leon V. Kochian | 95 | 266 | 31301 |
Abhay Ashtekar | 94 | 366 | 37508 |
Néstor Armesto | 93 | 369 | 26848 |
Manuel Hidalgo | 92 | 538 | 41330 |
Rafael de Cabo | 91 | 317 | 35020 |
Harald Mischak | 90 | 445 | 27472 |
Manuel Tena-Sempere | 87 | 351 | 23100 |